{"url":"https://lda.senate.gov/api/v1/filings/1fd3d89c-e894-4b89-8076-b5979b2dc861/","filing_uuid":"1fd3d89c-e894-4b89-8076-b5979b2dc861","filing_type":"Q2","filing_type_display":"2nd Quarter - Report","filing_year":2022,"filing_period":"second_quarter","filing_period_display":"2nd Quarter (Apr 1 - June 30)","filing_document_url":"https://lda.senate.gov/filings/public/filing/1fd3d89c-e894-4b89-8076-b5979b2dc861/print/","filing_document_content_type":"text/html","income":null,"expenses":"880000.00","expenses_method":"A","expenses_method_display":"A","posted_by_name":"Daniel Bachner","dt_posted":"2022-07-20T16:03:43-04:00","termination_date":null,"registrant_country":"United States of America","registrant_ppb_country":null,"registrant_address_1":"1399 New York Avenue NW","registrant_address_2":"Suite 600","registrant_different_address":false,"registrant_city":"Washington","registrant_state":"DC","registrant_zip":"20005","registrant":{"id":401049961,"url":"https://lda.senate.gov/api/v1/registrants/401049961/","house_registrant_id":null,"name":"ABBVIE, INC.","description":"Biopharmaceutical company","address_1":"1399 New York Avenue NW","address_2":"Suite 600","address_3":null,"address_4":null,"city":"Washington","state":"DC","state_display":"District of Columbia","zip":"20005","country":"US","country_display":"United States of America","ppb_country":"US","ppb_country_display":"United States of America","contact_name":"DANIEL BACHNER","contact_telephone":"+1 202-383-9616","dt_updated":"2026-01-08T13:23:19.652687-05:00"},"client":{"id":197319,"url":"https://lda.senate.gov/api/v1/clients/197319/","client_id":12,"name":"ABBVIE INC.","general_description":null,"client_government_entity":false,"client_self_select":true,"state":"DC","state_display":"District of Columbia","country":"US","country_display":"United States of America","ppb_state":"DC","ppb_state_display":"District of Columbia","ppb_country":"US","ppb_country_display":"United States of America","effective_date":"2013-02-25"},"lobbying_activities":[{"general_issue_code":"CPT","general_issue_code_display":"Copyright/Patent/Trademark","description":"H.R. 2891, Preserve Access to Affordable Generics and Biosimilars Act H.R. 2873, Affordable Prescriptions for Patients Through Promoting Competition Act of 2021 H.R. 2883, Stop Stalling Access to Affordable Medications H.R. 2884, Affordable Prescriptions for Patients Through Improvements to Patent Litigation Act S. 2891, Restoring the America Invents Act Patent litigation reform issues and issues related to post-grant proceedings at the USPTO Value of intellectual property","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":63900,"prefix":null,"prefix_display":null,"first_name":"DANIEL","nickname":null,"middle_name":null,"last_name":"BACHNER","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":62485,"prefix":null,"prefix_display":null,"first_name":"STEPHEN","nickname":null,"middle_name":null,"last_name":"SCANGO","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":90411,"prefix":null,"prefix_display":null,"first_name":"DORCAS","nickname":null,"middle_name":null,"last_name":"ADEKUNLE","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":106073,"prefix":null,"prefix_display":null,"first_name":"CRYSTAL","nickname":null,"middle_name":null,"last_name":"RILEY","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"HCR","general_issue_code_display":"Health Issues","description":"H.R. 3, Elijah E. Cummings Lower Cost Drugs Now Act H.R. 19, Lower Costs, More Cures Act H.R. 5260, Reduced Costs and Continued Cures Act H.R. 5801, Help Ensure Lower Patient Copays Act S. 2164, Lower Costs, More Cures Act of 2021 Drug cost and pricing policy issues Patient affordability issues Policy proposals relating to clinical trial diversity Patient Protection and Affordable Care Act; HHS Notice of Benefit and Payment Parameters for 2022 & 2023; Notice Requirement for Non-Federal Governmental Plans proposed rule Prescription Drug User Fee Act (PDUFA) reauthorization Issues related to the 340B program","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":62485,"prefix":null,"prefix_display":null,"first_name":"STEPHEN","nickname":null,"middle_name":null,"last_name":"SCANGO","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":63900,"prefix":null,"prefix_display":null,"first_name":"DANIEL","nickname":null,"middle_name":null,"last_name":"BACHNER","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":90411,"prefix":null,"prefix_display":null,"first_name":"DORCAS","nickname":null,"middle_name":null,"last_name":"ADEKUNLE","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":106073,"prefix":null,"prefix_display":null,"first_name":"CRYSTAL","nickname":null,"middle_name":null,"last_name":"RILEY","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"},{"id":12,"name":"White House Office"}]},{"general_issue_code":"MMM","general_issue_code_display":"Medicare/Medicaid","description":"Policy Proposals related to Medicare Part D and patient cost-sharing Department of Health and Human Services (HHS) drug policy issues and regulatory policy issues Medicaid Program; Establishing Minimum Standards in Medicaid State Drug Utilization Review (DUR) and Supporting Value-Based Purchasing (VBP) for Drugs Covered in Medicaid, Revising Medicaid Drug Rebate and Third Party Liability (TPL) Requirements (CMS 2482-F)","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":62485,"prefix":null,"prefix_display":null,"first_name":"STEPHEN","nickname":null,"middle_name":null,"last_name":"SCANGO","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":63900,"prefix":null,"prefix_display":null,"first_name":"DANIEL","nickname":null,"middle_name":null,"last_name":"BACHNER","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":90411,"prefix":null,"prefix_display":null,"first_name":"DORCAS","nickname":null,"middle_name":null,"last_name":"ADEKUNLE","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":106073,"prefix":null,"prefix_display":null,"first_name":"CRYSTAL","nickname":null,"middle_name":null,"last_name":"RILEY","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"TAX","general_issue_code_display":"Taxation/Internal Revenue Code","description":"H.R.5376, Build Back Better Act - provisions related to corporate taxes, Medicare, and prescription drug pricing Public Law 115-97 (formerly known as H.R. 1, Tax Cuts and Jobs Act) Implementation Policy proposals relating to economic activity in Puerto Rico International tax issues, including OECD digital taxation work program","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":63900,"prefix":null,"prefix_display":null,"first_name":"DANIEL","nickname":null,"middle_name":null,"last_name":"BACHNER","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":62485,"prefix":null,"prefix_display":null,"first_name":"STEPHEN","nickname":null,"middle_name":null,"last_name":"SCANGO","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":90411,"prefix":null,"prefix_display":null,"first_name":"DORCAS","nickname":null,"middle_name":null,"last_name":"ADEKUNLE","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":106073,"prefix":null,"prefix_display":null,"first_name":"CRYSTAL","nickname":null,"middle_name":null,"last_name":"RILEY","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"},{"id":41,"name":"Treasury, Dept of"}]}],"conviction_disclosures":[],"foreign_entities":[],"affiliated_organizations":[]}